{"generic":"Tbo-Filgrastim","drugs":["Granix","Tbo-Filgrastim"],"mono":{"0":{"id":"jy61s0","title":"Generic Names","mono":"Tbo-Filgrastim"},"1":{"id":"jy61s1","title":"Dosing and Indications","sub":[{"id":"jy61s1b4","title":"Adult Dosing","mono":"<ul><li>Evaluate CBC prior to administration of chemotherapy, then monitor twice a week until recovery<\/li><li><b>Neutropenia (Severe), In nonmyeloid malignancies following myelosuppressive chemotherapy; Prophylaxis:<\/b> 5 mcg\/kg\/day SUBQ no earlier than 24 hours after myelosuppressive chemotherapy; continue until neutrophil count passes nadir and has recovered to normal range; do not give within 24 hours prior to chemotherapy<\/li><\/ul>"},{"id":"jy61s1b5","title":"Pediatric Dosing","mono":"Safety and effectiveness have not been established in pediatric patients "},{"id":"jy61s1b6","title":"Dose Adjustments","mono":"<b>Renal impairment, mild:<\/b> No dosage adjustment needed; moderate to severe impairment has not been evaluated "},{"id":"jy61s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Neutropenia (Severe), In nonmyeloid malignancies following myelosuppressive chemotherapy; Prophylaxis<br\/>"}]},"3":{"id":"jy61s3","title":"Contraindications\/Warnings","sub":[{"id":"jy61s3b9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"jy61s3b10","title":"Precautions","mono":"<ul><li>Hematologic:<\/li><li>-- capillary leak syndrome may occur with human granulocyte colony-stimulating factors; monitoring recommended<\/li><li>-- potentially fatal splenic rupture may occur with human granulocyte colony-stimulating factors; discontinue use if upper abdominal or shoulder pain occurs<\/li><li>-- sickle cell disease; severe and sometimes fatal sickle cell crises may occur with human granulocyte colony-stimulating factors; discontinue use if crisis occurs<\/li><li>Immunologic:<\/li><li>-- serious allergic reactions (eg, anaphylaxis) may occur with human granulocyte colony-stimulating factors, even with initial exposure; discontinue use if occurs<\/li><li>-- serious, allergic reactions to filgrastim or pegfilgrastim; do not administer<\/li><li>Respiratory:<\/li><li>-- acute respiratory distress syndrome may occur with human granulocyte colony-stimulating factors; discontinue use if occurs<\/li><li>Other:<\/li><li>-- tumor growth, including myeloid malignancies and myelodysplasia (unapproved uses); may occur<\/li><\/ul>"},{"id":"jy61s3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jy61s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jy61s4","title":"Drug Interactions","sub":{"1":{"id":"jy61s4b14","title":"Major","mono":"<ul>Topotecan (theoretical)<\/ul>"}}},"5":{"id":"jy61s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Hematologic:<\/b>Leukocytosis (Less than 1%)<\/li><li><b>Musculoskeletal:<\/b>Bone pain (3.4%)<\/li><\/ul>"},"6":{"id":"jy61s6","title":"Drug Name Info","sub":{"0":{"id":"jy61s6b17","title":"US Trade Names","mono":"Granix<br\/>"},"2":{"id":"jy61s6b19","title":"Class","mono":"Colony Stimulating Factor<br\/>"},"3":{"id":"jy61s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jy61s6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jy61s7","title":"Mechanism Of Action","mono":"Tbo-filgrastim is a granulocyte colony-stimulating factor (G-CSF) that increases neutrophil counts and activity by binding to G-CSF receptors and stimulating differentiation commitment and some end-cell functional activation.<br\/>"},"8":{"id":"jy61s8","title":"Pharmacokinetics","sub":{"0":{"id":"jy61s8b23","title":"Absorption","mono":"<ul><li>Bioavailability, subQ: 33%<\/li><li>Tmax, subQ: 4 to 6 hours<\/li><\/ul>"},"4":{"id":"jy61s8b27","title":"Elimination Half Life","mono":"3.2 to 3.8 hours <br\/>"}}},"9":{"id":"jy61s9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>If syringes are removed from refrigerator, administer within 5 days or return to the refrigerator for storage up to the expiration date<\/li><li>Avoid shaking<\/li><li>Syringes are single use; discard any unused portion<\/li><li>Assess each patient for ability to competently self-administer<\/li><li>Recommended injection sites are abdomen (excluding 2 inches around the navel), front of middle thighs, upper outer area of buttocks, and upper back portion of upper arms<\/li><li>Do not inject into areas that are red, tender, bruised, hard, or that have scars or stretch marks<\/li><li>Rotate injection sites<\/li><\/ul>"},"10":{"id":"jy61s10","title":"Monitoring","mono":"<ul><li>decreased duration of neutropenia-related sequelae (eg, fever, infections) and reduced neutrophil recovery time are indicative of efficacy<\/li><li>CBC; baseline and twice weekly until neutrophil recovery; including differential<\/li><\/ul>"},"11":{"id":"jy61s11","title":"How Supplied","mono":"<b>Granix<\/b><br\/>Subcutaneous Solution: 480 MCG\/0.8 ML, 300 MCG\/0.5 ML<br\/>"},"13":{"id":"jy61s13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to avoid administration in areas that are tender, red, bruised, hardened or areas that have scarring or stretch marks.<\/li><li>Warn female patients of childbearing potential to avoid becoming pregnant while taking this drug as fetal harm may occur.<\/li><li>Drug may cause bone pain.<\/li><li>Instruct patient to report symptoms of splenic enlargement or rupture (eg, left upper abdominal or left shoulder pain).<\/li><li>Advise patient to report symptoms of dyspnea.<\/li><li>Tell patient to report symptoms of allergic reaction (ie, anaphylaxis, rash, urticaria).<\/li><li>Encourage patient to report symptoms of infection (ie, fever, redness, swelling).<\/li><li>If self administering, teach patient proper technique and placement of injections.<\/li><\/ul>"}}}